Brief: Novartis: European Medicines Agency (EMA) Has Adopted A Positive Opinion Recommending Marketing Authorization For Remibrutinib
27/02/2026 11:30
Feb 27 (Reuters) - Novartis NOVN.S: ANNOUNCED TODAY THAT COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF EUROPEAN MEDICINES AGENCY (EMA) HAS ADOPTED A POSITIVE OPINION RECOMMENDING MARKETING AUTHORIZATION FOR REMIBRUTINIB RECEIVES POSITIVE CHMP OPINION FOR REMIBRUTINIB IN CHRONIC SPONTANEOUS URTICARIA (CSU) Source text: ID:nGNE9c73qF Further company coverage: NOVN.S (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'